AASLD News

HCV Guidance Updates Recommendations For Identification And Management Of Chronic Hep C

HCVguidelines.org — a website developed by the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America to provide up-to-date guidance on the management of hepatitis C — was recently revised to reflect important developments in the identification and management of chronic hepatitis C (HCV).

Universal Hepatitis C Screening of Pregnant Women More Cost-Effective Than Risk-Based Approach

Media Contact: Caroline Laurin Phone: (703) 299-9766 Onsite phone: (415)-978-3601 Email: media@aasld.org San Francisco – Preliminary data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that universal screening of pregnant women at risk for hepatitis C virus (commonly called HCV) infection is a more efficient and

Combined Glecaprevir and Pibrentasvir Found Highly Effective in Chronic Hepatitis C Patients Who Have Failed Other Therapies

Media Contact: Caroline Laurin Phone: (703) 299-9766 Onsite phone: (415) 978-3601 Email: media@aasld.org San Francisco – Data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found the combination of glecaprevir and pibrentasvir is highly effective and well tolerated in patients with chronic hepatitis C virus (commonly

Weight-Loss Surgery Effectively Reduces Weight and Lowers Risk of Post- Liver Transplant Complications in Obese Patients

Media Contact: Caroline Laurin Phone: (703) 299-9766 Onsite phone: (415)-978-3601 Email: media@aasld.org San Francisco – Preliminary data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that weight-loss surgery prior to liver transplantation is superior to medical weight loss approaches at achieving sustained

Clinically Significant Liver Toxicity Related To Anti-cancer Drugs Is Rare But Often Leads To Discontinuation Of Treatment

Preliminary data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that patients treated with immune checkpoint inhibitors rarely develop severe liver toxicity, but the majority of those who do permanently stop this cancer treatment. None of the patients developed liver failure as a result of this treatment.

Under-Immunization Still a Major Problem in Pediatric Liver Transplant Patient Population

Media Contact: Caroline Laurin Phone: (703) 299-9766 Onsite phone: (415)-978-3601 Email: media@aasld.org San Francisco – Data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that more than half of pediatric liver transplant recipients are under-immunized at the time of their transplant and are at increased risk

Five Years Of Regular Aspirin Use Helps Prevent Common Liver Cancer

Data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that taking a regular aspirin is associated with a dose-dependent reduction in the risk of hepatocellular carcinoma, one of the most common liver cancers.

Nonalcoholic Fatty Liver Disease Patients Have Higher Rates of All Non-Liver-Related Cancers

Media Contact: Caroline Laurin Phone: (703) 299-9766 Onsite phone: (415)-978-3601 Email: media@aasld.org San Francisco – Preliminary data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that rates of malignancy occurring outside of the liver were higher in adults with nonalcoholic fatty liver disease than among

Preemptive Antiviral Therapy Prevents Chronic Hepatitis C Infection In Heart Transplant Patients Who Receive Infected Donor Organs

Preliminary data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that pre-emptive administration of pan-genotypic, direct-acting antiviral therapy prevents chronic hepatitis C virus infection in hepatitis C-negative cardiac transplant patients who receive donor hearts infected with the virus.

A Healthy Lifestyle May Help Prevent Liver-related Deaths

Data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that a substantial burden of hepatocellular carcinoma (HCC) and cirrhosis-related deaths may be prevented by lifestyle modifications to diet, alcohol use and exercise.

People With Hepatitis C Who Actively Inject Illegal Drugs Have High Rates Of Hepatitis C Treatment Adherence And Cure

Preliminary data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that people who inject drugs who are infected with the hepatitis C virus have high rates of hepatitis C treatment adherence (completion of their treatment), and sustained virologic response. Based on these findings, researchers conclude these

Normothermic Machine Perfusion Can Salvage Fatty Livers For Transplantation

Data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that using normothermic machine perfusion to preserve steatotic livers leads to altered lipid structure and metabolism and may result in more successful transplantation of these organs.

Liver Cancer Combined With Other Liver Diseases Driving Higher Death Rate And Health Care Costs For Us Seniors

Data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that hospitalizations and death are increasing among Medicare recipients with hepatocellular carcinoma, mainly due to co-existing alcoholic liver disease, hepatitis C virus infection (commonly called HCV) and nonalcoholic fatty liver disease (commonly called

NAFLD Patients Less Likely To Lose Weight, Need More Effective Weight Loss Strategies

Data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that obese individuals with nonalcoholic fatty liver disease (NAFLD) were less likely to achieve a medically recommended five percent loss of body weight at three months on a very-low-calorie diet compared to obese counterparts without NAFLD.